Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms

Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms

Blog Article

Breast cancer is a common malignant tumor in women, with a highest incidence and mortality among all of DOPHILUS PLUS the female malignant tumors.Notably, targeted therapy has achieved impressive success in the treatment of breast cancer.As one class of the anti-tumor targeted therapeutics, Cyclin-Dependent Kinases 4/6CDK4/6inhibitors have shown good clinical activity in treating breast cancer.

Nevertheless, despite the promising clinical outcomes, intrinsic or acquired resistance to CDK4/6 inhibitors has limited the benefits of this novel target therapy.In the present review, we provide an overview of the currently known molecular mechanisms of resistance to CDK4/6 inhibitors, and discuss the potential Lysine strategies to overcoming drug resistance improving the outcomes for breast cancer patients treated with CDK4/6 inhibitors.